Drug intelligence / Profile preview

JKN2306

Development stage: Phase 1
Lead developer: Joincare Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JKN2306 is an investigational, highly selective second-generation Nav1.8 inhibitor being developed by Joincare Pharmaceutical Group for the treatment of acute pain. As a voltage-gated sodium channel primarily expressed in peripheral sensory neurons, Nav1.8 is a key target for developing non-opioid and non-addictive analgesics. The drug is formulated as an oral tablet and is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile, including the impact of food on drug absorption in healthy volunteers.

Targets

SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on JKN2306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JKN2306.

Explore the full profile